Search
Evolus Inc
EOLSAdd to Watchlist
8.155USD
+0.135+1.68%
Close 08-14 16:00（ET）Quotes delayed by 15 min
538.34MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Evolus Inc is 8.57, ranking 27 out of 156 in the Pharmaceuticals industry. The average price target is 19.50, with a high of 20.00 and a low of 14.00.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
14.667
Target Price
+82.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Evolus Inc
EOLS
7
Amgen Inc
AMGN
37
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Evolus Inc's expected revenue for the next quarter?
Evolus Inc's expected revenue is 77.92M.
What is Evolus Inc's price target?
Analysts forecast that Evolus Inc's price target is USD 19.50, with the highest forecast at USD 20.00 and the lowest forecast at USD 14.00.
How have Evolus IncEOLS's recent earnings per share performed?
The market expectation was USD -0.12, while Evolus IncEOLS's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.06.
What is the analyst rating for Evolus Inc?
Based on the ratings of Evolus Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.